The company recently published a clinical study showing the test could distinguish between bacterial and viral infections with an area under the curve of .94.
The study found that using Veristrat to guide patient therapy decreased the total lifetime direct medical cost per patient by $135.
The company has launched an early-access program for researchers interested in using the system for fractionation of proteomic samples.
OVA2 replaces two of the five OVA1 protein markers with new biomarkers and offers improved specificity and positive predictive value, the company said.
Product revenues, comprised of OVA1 sales, were also flat at $1.5 million, as were licensing revenues at $113,000.
In Science this week: self-assembly of DNA components in solution, and more.
Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.
A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.
With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.